Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000400 · ClinicalTrials.gov registry record · Phase 2
Alendronate and/or Parathyroid Hormone for Osteoporosis
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00000400: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00000400 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 176 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000400, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
Interventions
- DRUG alendronate
- DRUG Human parathyroid hormone [hPTH-(1-34)]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 1999-08 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00000400 record still lists
NCT00000400 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 2 interventions - of which alendronate is the first listed.
NCT00000400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000400 about?
NCT00000400 is a clinical study titled "Alendronate and/or Parathyroid Hormone for Osteoporosis". This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH...
What is the current status of trial NCT00000400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 1999-08. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00000400?
The interventions under investigation include: alendronate (DRUG), Human parathyroid hormone [hPTH-(1-34)] (DRUG).
Who is sponsoring clinical trial NCT00000400?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000400's enrollment target sits among peer trials
176 394th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia